Neuroleptic-related dyskinesias in children and adolescents

Journal of Clinical Psychiatry

Volumn 62, Issue 12, 2001, Pages 967-974

  Connor, D F ^a   Fletcher, K E ^a   Wood, J S ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PSYCHOSTIMULANT AGENT; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADOLESCENT; ADULT; ARTICLE; BEHAVIOR DISORDER; CHILD; DEVELOPMENTAL DISORDER; DRUG INDUCED DISEASE; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INVOLUNTARY MOVEMENT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RATING SCALE; REGRESSION ANALYSIS; RISK FACTOR; TARDIVE DYSKINESIA;

EID: 0035658215     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v62n1209     Document Type: Article

References (29)

1. Haloperidol-related dyskinesias and pre- and perinatal complications in autistic children
2. Neuroleptic-related dyskinesias in autistic children: A prospective longitudinal study
3. Tardive dyskinesia, tardive dystonia, and tardive Tourette's syndrome in children and adolescents
4. Antipsychotics in children and adolescents
5. Case series: Spectrum of neuroleptic-induced movement disorders and extrapyramidal side effects in childhood-onset schizophrenia
6. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients
7. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol
8. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes
9. Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients
10. Expected incidence of tardive dyskinesia associated with atypical antipsychotics
11. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality
12. Tardive dyskinesia: Prevalence, incidence, and risk factors
13. Extrapyramidal syndromes in neuroleptic-treated patients: Prevalence, risk factors, and association with tardive dyskinesia
14. Risk of tardive dyskinesia in older patients
15. Tardive dyskinesia in mentally retarded children, adolescents, and young adults: North Carolina and Michigan studies
16. Psychoactive medication prescribing practices for US children: Gaps between research and clinical practice
17. How to examine patients using the Abnormal Involuntary Movement Scale
18. Research diagnoses for tardive dyskinesia
19. Prevalence and patterns of psychotropic and anticonvulsant medication use in children and adolescents referred to residential treatment
20. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III
21. Tardive dyskinesia and other clinical consequences of neuroleptic treatment in children and adolescents
22. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
23. Abnormal involuntary movements in neuroleptic-naive children and adolescents
24. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients
25. Attention deficit hyperactivity disorder may be a risk factor for treatment-emergent tardive dyskinesia induced by risperidone